Subscribe to RSS
DOI: 10.1055/s-2003-40451
Behavioural and Psychological Symptoms of Dementia (BPSD): Effects of EGb 761®
Publication History
Publication Date:
07 July 2003 (online)
Dementia patients often present with behavioural and psychological symptoms, with prevalence rates reaching 90 %. It is therefore important to know whether an antidementia drug that improves cognitive function can also reduce the burden of behavioural and psychological symptoms of dementia, and whether it can improve cognitive function in patients suffering from such non-cognitive symptoms. Therefore, three types of study with Ginkgo special extract EGb 761® (definition see editorial) were reviewed: 1) studies on patients with impairment of cerebral function or dementia associated with behavioural and psychological symptoms (BPSD); 2) studies on patients suffering from impairment of cerebral function and depression; 3) dementia studies on patient samples with a high prevalence of BPSD. Compared to placebo, EGb 761® improved these symptoms significantly in all studies that used a scale to measure the presence and intensity of BPSD. Moreover, EGb 761® was found to be superior to placebo with respect to improvement in cognitive function, daily living activities and global assessment in dementia patients suffering from BPSD. It may be concluded that EGb 761® is of particular interest to patients with dementia and BPSD since it improves both the patient’s cognitive ability and behavioural and psychological symptoms.
Key words
Ginkgo - EGb 761® - Dementia - BPSD - Depression - HAMD - SCAG
References
- 1 Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt. 1906; 23 1129-1136
- 2 American Psychiatric A ssociation. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. DSM-IV. Washington, DC; American Psychiatric Association 1999
- 3 Blessed G, Tomlinson B E, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Brit J Psychiat. 1968; 114 797-811
- 4 Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H J. et al . The effects of donepezil in Alzheimer’s disease - Results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10 237-244
- 5 Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study G roup. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. International Journal of Geriatric Psychopharmacology. 1998; 1 55-65
- 6 Drevets W C, Rubin E H. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989; 25 39-48
- 7 Düker H, Lienert G A. KLT-Konzentrations-Leistungs-Test. Handanweisung. Göttingen; Hogrefe 1965
- 8 Erzigkeit H. Der Syndrom-Kurztest zur Erfassung von Aufmerksamkeits- und Gedächtnisstörungen. Vaterstetten; Vless 1986
- 9 Finkel S I, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of demenia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996; 8 (Suppl 3) 497-500
- 10 Finkel S I. Module 1. An introduction to BPSD. In Finkel SI, editor. Behavioral and psychological symptoms of dementia. Educational Pack. Macclesfield; Gardiner-Caldwell 1998: p. 1-19
- 11 Folstein M F, Folstein S E, McHugh P R. ”Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975; 12 189-198
- 12 Förstl H. Neuropathology of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2000; 12 (Suppl 1) 77-81
- 13 Guy W (ed.). ECDEU Assessment Manual for Psychopharmacology. Rockville, Md; US Dept. of Health, Education and Welfare, National Institute of Mental Health 1976: p. 218-222
- 14 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23 56-62
- 15 Hofferberth B. The efficacy of EGb 761® in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacology. 1994; 9 215-222
- 16 Hope T, Keene J, Fairburn C G, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer’s disease. A longitudinal study. Br J Psychiatry. 1999; 174 39-44
- 17 Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T. et al . Free radicals and superoxide dismutase in blood of patients with Alzheimer’s disease and vascular dementia. J Neurol Sci. 1997; 153 76-81
- 18 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hoerr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiat. 1996; 29 47-56
- 19 Knapp M J, Knopman D S, Solomon P R, Pendlebury W W, Davis C S, Gracon S I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA. 1994; 271 985-991
- 20 Le Bars P L, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg AF for the North American EGb Study G roup. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997; 278 1327-1332
- 21 Lebowitz B D. Behavioral and psychological symptoms of dementia: A clinical and research update. Int Psychogeriatr. 2000; 12 (Suppl 1) 19-21
- 22 Levy M L, Cummings J L, Fairbanks L A, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry. 1996; 153 1438-1443
-
23 Luxenberg J. Module 2. Clinical issues. In Finkel SI, editor
Behavioral and psychological symptoms of dementia. Educational pack. Macclesfield; Gardiner-Caldwell 1998: p. 1-29 - 24 Lyketsos C G, Steinberg M, Tschanz J T, Norton M C, Steffens D C, Breitner J CS. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry. 2000; 157 708-714
- 25 Mancini M, Agozzino B, Bompani R. Clinical and therapeutic effects of Ginkgo biloba extract (EGb) compared to placebo in the treatment of patients affected by senile psychorganic dementia on an arteriosclerotic basis. Gazz Med Ital - Arch Sci Med. 1993; 152 69-80
- 26 Mega M S, Cummings J L, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996; 46 130-135
- 27 Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change. Brit J Psychiat. 1979; 134 382-389
- 28 Münch G, Schinzel R, Loske C, Wong A, Durany N, Li J J. et al . Alzheimer’s disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm. 1998; 105 439-446
- 29 Oswald W D, Fleischmann U M. Nuremberg Gerontopsychological Inventory (NAI). Göttingen; Hogrefe 1995
-
30 Porsolt R D, Martin P, Fromage S, Lenègre A, Drieu K. Anti-stress effects of EGb 761® in rodent models. In Cristen Y, Costentin J, Lacour M, editors
Effects of Ginkgo biloba extract (EGb 761) on the central nervous system . Paris; Elsevier 1992: p. 135-145 -
31 Prilipko L. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In Packer L, Prilipko L, Christen Y, editors
Free radicals in the brain . Berlin; Springer 1992: p. 146-152 - 32 Ramassamy C, Christen Y, Clostre F, Costentin J. The Ginkgo biloba extract, EGb 761®, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol. 1992; 44 943-945
- 33 Rapin J R, Lamproglou I, Drieu K, DeFeudis F V. Demonstration of the ”anti-stress” activity of an extract of Ginkgo biloba (EGb 761®) using a discrimination learning task. Gen Pharmac. 1994; 25 1009-1016
- 34 Reisberg B, Borenstein J, Salob S P, Ferris S H. Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment. J Clin Psychiatry. 1987; 48 (Suppl) 9-15
- 35 Reisberg B, Ferris S H, de Leon M J, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139 1136-1139
- 36 Rogers S I, Farlow M R, Doody R S, Mohs R, Friedhoff LT and the Donepezil Study G roup. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998; 50 136-145
- 37 Rosen W G, Mohs R C, Davis K L. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984; 141 1356-1364
- 38 Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin H B,. et al . Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Brit Med J. 1999; 318 633-640
- 39 Sattel H, Geiger-Kabisch C, Schreiter-Gasser U, Besthorn C, Förstl H. Häufigkeit und Bedeutung ”nicht-kognitiver” Symptome bei der Demenz vom Alzheimer-Typ: produktiv psychotische Symptomatik, depressive Störungen und Störungen des Verhaltens. Z Gerontol. 1993; 26 275-279
- 40 Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: efficacy of Ginkgo biloba extract EGb 761® in combination with antidepressants. Geriatrie Forschung. 1993; 3 45-53
- 41 Schwartz G E. Development and validation of the Geriatric Evaluation by Relative’s Rating Instrument (GERRI). Psychol Rep. 1983; 53 479-488
- 42 Shader R I, Harmatz J S, Salzman C. A new scale for clinical assessment on geriatric populations: SANDOZ Clinical Assessment Geriatric (SCAG). J Am Geriat Soc. 1974; 22 107-113
- 43 Stocksmeier U, Eberlein M. Depressive Verstimmung bei Hirnleistungsstörungen. Wirkung eines Ginkgo-biloba-Extraktes in Doppelblind-Studie überprüft. TW Neurologie Psychiatrie. 1992; 6 74-76
- 44 Weidenhammer W, Fischer B. c. I.-Skala, ein Selbstbeurteilungsverfahren zur Objektivierung leichter cerebraler Insuffizienzen. Ebersberg; Vless-Test 1987
- 45 Weitbrecht W U, Jansen W. Ginkgo biloba extract in the treatment of primary degenerative dementia. Placebo-controlled, double-blind and comparative study. Fortschr Med. 1986; 104 199-202
- 46 Winter J C, Timineri D. The discriminative stimulus properties of EGb 761®, an extract of Ginkgo biloba. Pharmacol Biochem Behav. 1999; 62 543-547
- 47 Zhang X Y, Zhou D F, Su J M, Zhang P Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol. 2001; 21 85-88
- 48 Zhang X Y, Zhou D F, Zhang P Y, Wu G Y, Su J M, Cao L Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001; 62 878-883
Dr. med. Robert Hoerr
Leiter Geriatrie/ZNS
Dr. Willmar Schwabe GmbH & Co. KG
Willmar-Schwabe-Str. 4
76227 Karlsruhe
Germany